Literature DB >> 2546785

Chlormethiazole: neurochemical actions at the gamma-aminobutyric acid receptor complex.

E J Moody1, P Skolnick.   

Abstract

Chlormethiazole has been extensively employed as a sedative/hypnotic and anticonvulsant for more than 25 years. While pharmacological and electrophysiological studies have implicated the GABAA receptor complex in these actions, neurochemical findings have not been consistent with this conclusion. We now present evidence that pharmacologically relevant concentrations of chlormethiazole perturb the GABAA receptor complex. Chlormethiazole was found to increase 36Cl- uptake into rat cortical synaptoneurosomes in a concentration-dependent (EC50 = 48 +/- 3 microM; Emax = 8.9 +/- 0.8 nmol Cl-/mg protein per 5 s), picrotoxin-sensitive fashion. Chlormethiazole was also found to inhibit the binding of the 'cage' convulsant [35S]t-butylbicyclophosphorothionate to rat cortical membranes (IC50 = 58.6 +/- 0.6 microM) through an increase in the apparent KD of this radioligand. Moreover, at these concentrations chlormethiazole did not affect pentobarbital-enhanced [3H]flunitrazepam binding, but inhibited [3H]flunitrazepam binding with a low potency (IC50 = 1.6 +/- 0.2 mM). These findings provide neurochemical evidence that pharmacologically relevant concentrations of chlormethiazole can perturb the GABAA receptor complex, and suggest that this compound acts at a distinct locus from other sedative/hypnotics such as barbiturates, benzodiazepines and GABAmimetics.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2546785     DOI: 10.1016/0014-2999(89)90242-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

Review 1.  Clinical trials for cytoprotection in stroke.

Authors:  Lise A Labiche; James C Grotta
Journal:  NeuroRx       Date:  2004-01

Review 2.  The treatment of sundowning. A selective review of pharmacological and nonpharmacological studies.

Authors:  S McGaffigan; D L Bliwise
Journal:  Drugs Aging       Date:  1997-01       Impact factor: 3.923

3.  Novel analogues of chlormethiazole are neuroprotective in four cellular models of neurodegeneration by a mechanism with variable dependence on GABA(A) receptor potentiation.

Authors:  Lawren Vandevrede; Ehsan Tavassoli; Jia Luo; Zhihui Qin; Lan Yue; David R Pepperberg; Gregory R Thatcher
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

4.  Action of chlormethiazole in a model of ethanol withdrawal.

Authors:  A R Green; E M Davies; H J Little; M A Whittington; A J Cross
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  On the regulation of ischaemia-induced glutamate efflux from rat cortex by GABA; in vitro studies with GABA, clomethiazole and pentobarbitone.

Authors:  R M Nelson; A R Green; D G Lambert; A H Hainsworth
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

6.  Counteraction of the rapid tolerance to 8-OH-DPAT-induced corticosterone secretion in rats by activation of the GABAA receptor-chloride channel complex.

Authors:  D Kelder; S B Ross
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

7.  Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine.

Authors:  H A Baldwin; M I Colado; T K Murray; R J De Souza; A R Green
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

8.  Neuroprotective activity of chlormethiazole following transient forebrain ischaemia in the gerbil.

Authors:  A J Cross; J A Jones; H A Baldwin; A R Green
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

9.  Investigation of the effect of chlormethiazole on cerebral chemistry in neurosurgical patients: a combined study of microdialysis and a neuroprotective agent.

Authors:  P J Hutchinson; M T O'Connell; J P Coles; D A Chatfield; M R Coleman; P G Al-Rawi; C R Kett-White; A K Gupta; D K Menon; S J Boniface; M Heazell; P J Kirkpatrick; J D Pickard
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.